Curanex Provides Operational Update on Key Regulatory Milestones

robot
Abstract generation in progress

Curanex Pharmaceuticals Inc. announced the successful completion of a GMP-compliant pilot-scale batch of its lead botanical drug candidate, Phyto-N. This milestone is crucial for its planned Investigational New Drug (IND) submission for ulcerative colitis, targeted for Q4 2026. The company is now advancing GLP toxicology and pharmacokinetic studies to support the regulatory submission.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments